These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23281290)

  • 1. Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer.
    Abdolahi M; Shahbazi-Gahrouei D; Laurent S; Sermeus C; Firozian F; Allen BJ; Boutry S; Muller RN
    Contrast Media Mol Imaging; 2013; 8(2):175-84. PubMed ID: 23281290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer.
    Tse BW; Cowin GJ; Soekmadji C; Jovanovic L; Vasireddy RS; Ling MT; Khatri A; Liu T; Thierry B; Russell PJ
    Nanomedicine (Lond); 2015 Feb; 10(3):375-86. PubMed ID: 25407827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels.
    Sillerud LO
    Int J Nanomedicine; 2016; 11():357-71. PubMed ID: 26855574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
    Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
    Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative [Fe]MRI determination of the dynamics of PSMA-targeted SPIONs discriminates among prostate tumor xenografts based on their PSMA expression.
    Sillerud LO
    J Magn Reson Imaging; 2018 Aug; 48(2):469-481. PubMed ID: 29331081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles.
    Zhu Y; Sun Y; Chen Y; Liu W; Jiang J; Guan W; Zhang Z; Duan Y
    Int J Mol Sci; 2015 Apr; 16(5):9573-87. PubMed ID: 25927579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.
    Nagesh PKB; Johnson NR; Boya VKN; Chowdhury P; Othman SF; Khalilzad-Sharghi V; Hafeez BB; Ganju A; Khan S; Behrman SW; Zafar N; Chauhan SC; Jaggi M; Yallapu MM
    Colloids Surf B Biointerfaces; 2016 Aug; 144():8-20. PubMed ID: 27058278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging.
    Serda RE; Adolphi NL; Bisoffi M; Sillerud LO
    Mol Imaging; 2007; 6(4):277-88. PubMed ID: 17711783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate.
    Moffatt S; Papasakelariou C; Wiehle S; Cristiano R
    Gene Ther; 2006 May; 13(9):761-72. PubMed ID: 16453011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.
    Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
    Prostate; 2010 Sep; 70(12):1286-94. PubMed ID: 20623630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
    Bander NH; Trabulsi EJ; Kostakoglu L; Yao D; Vallabhajosula S; Smith-Jones P; Joyce MA; Milowsky M; Nanus DM; Goldsmith SJ
    J Urol; 2003 Nov; 170(5):1717-21. PubMed ID: 14532761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
    Kinoshita Y; Kuratsukuri K; Newman N; Rovito PM; Kaumaya PT; Wang CY; Haas GP
    Prostate Cancer Prostatic Dis; 2005; 8(4):359-63. PubMed ID: 16172607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of MUC1-expressing ovarian cancer by C595 monoclonal antibody-conjugated SPIONs using MR imaging.
    Shahbazi-Gahrouei D; Abdolahi M
    ScientificWorldJournal; 2013; 2013():609151. PubMed ID: 24194685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized Anti-Prostate-Specific Membrane Antigen Single-Chain Variable Fragment-Loaded Nanobubbles as a Novel Targeted Ultrasound Contrast Agent for the Diagnosis of Prostate Cancer.
    Ding Y; Cao Q; Qian S; Chen X; Xu Y; Chen J; Shen H
    J Ultrasound Med; 2020 Apr; 39(4):761-773. PubMed ID: 31702068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.
    Muthumani K; Marnin L; Kudchodkar SB; Perales-Puchalt A; Choi H; Agarwal S; Scott VL; Reuschel EL; Zaidi FI; Duperret EK; Wise MC; Kraynyak KA; Ugen KE; Sardesai NY; Joseph Kim J; Weiner DB
    Cancer Immunol Immunother; 2017 Dec; 66(12):1577-1588. PubMed ID: 28819703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
    McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
    Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of an antibody-labeled super-paramagnetic iron oxide contrast agent targeting prostate cancer cells for magnetic resonance imaging.
    Bates D; Abraham S; Campbell M; Zehbe I; Curiel L
    PLoS One; 2014; 9(5):e97220. PubMed ID: 24819929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanohybride Materials Based on Magnetite-Gold Nanoparticles for Diagnostics of Prostate Cancer: Synthesis and In Vitro Testing.
    Machulkin AE; Garanina AS; Zhironkina OA; Beloglazkina EK; Zyk NV; Savchenko AG; Kotelyanskii VE; Mazhuga AG
    Bull Exp Biol Med; 2016 Sep; 161(5):706-710. PubMed ID: 27704352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells.
    Zare H; Rajabibazl M; Rasooli I; Ebrahimizadeh W; Bakherad H; Ardakani LS; Gargari SL
    Int J Biol Markers; 2014 Jun; 29(2):e169-79. PubMed ID: 24425321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.